The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: Data from the GISSI-heart failure (GISSI-HF) trial

Serge Masson, Roberto Latini, Emanuele Carbonieri, Luciano Moretti, Maria Grazia Rossi, Santo Ciricugno, Valentina Milani, Roberto Marchioli, Joachim Struck, Andreas Bergmann, Aldo P. Maggioni, Gianni Tognoni, Luigi Tavazzi

Research output: Contribution to journalArticle

Abstract

Aims Though various neurohormonal systems are concurrently activated during heart failure (HF), their biological effectors are not always easy to measure due to their short life in vivo, instability in biological samples, or very low concentrations. We measured the plasma concentrations of four stable precursor fragments of neurohormonal systems in patients with chronic HF and evaluated their relationship with outcome.Methods and resultsThis study was performed in 1237 patients with chronic and stable HF enrolled in the GISSI-heart failure trial (GISSI-HF). The following four precursor fragments, mid-regional pro-atrial natriuretic peptide (MR-proANP), mid-regional pro-adrenomedullin (MR-proADM), C-terminal pro-endothelin-1 (CT-proET-1) and C-terminal pro-vasopressin (CT-proAVP or copeptin), were measured at randomization and after 3 months. Baseline concentrations were independent predictors of clinical outcome (median follow-up 3.9 years). The addition of MR-proANP improved net reclassification for mortality when added to multivariable models based on clinical risk factors alone [net reclassification improvement (NRI) = 0.12, P = 0.0007] or together with NT-proBNP (NRI = 0.06, P = 0.01). Changes in MR-proANP concentrations were related to mortality [HR (95 CI) 1.38 (0.99-1.93), P = 0.0614 and 1.58 (1.13-2.21), P = 0.0078 in the middle and highest vs. lowest tertiles], while changes in the other markers were not.ConclusionIn patients with chronic and stable HF enrolled in a multicentre, randomized, clinical trial, measurement of stable precursor fragments of vasoactive peptides provided prognostic information independent of natriuretic peptides which are currently the best biomarkers for risk stratification.

Original languageEnglish
Pages (from-to)338-347
Number of pages10
JournalEuropean Journal of Heart Failure
Volume12
Issue number4
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Peptide Fragments
Heart Failure
Atrial Natriuretic Factor
Adrenomedullin
Natriuretic Peptides
Mortality
Endothelin-1
Random Allocation
Vasopressins
Randomized Controlled Trials
Biomarkers

Keywords

  • Adrenomedullin
  • Endothelin
  • Heart failure
  • Natriuretic peptides
  • Prognosis
  • Vasopressin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure : Data from the GISSI-heart failure (GISSI-HF) trial. / Masson, Serge; Latini, Roberto; Carbonieri, Emanuele; Moretti, Luciano; Rossi, Maria Grazia; Ciricugno, Santo; Milani, Valentina; Marchioli, Roberto; Struck, Joachim; Bergmann, Andreas; Maggioni, Aldo P.; Tognoni, Gianni; Tavazzi, Luigi.

In: European Journal of Heart Failure, Vol. 12, No. 4, 04.2010, p. 338-347.

Research output: Contribution to journalArticle

Masson, S, Latini, R, Carbonieri, E, Moretti, L, Rossi, MG, Ciricugno, S, Milani, V, Marchioli, R, Struck, J, Bergmann, A, Maggioni, AP, Tognoni, G & Tavazzi, L 2010, 'The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: Data from the GISSI-heart failure (GISSI-HF) trial', European Journal of Heart Failure, vol. 12, no. 4, pp. 338-347. https://doi.org/10.1093/eurjhf/hfp206
Masson, Serge ; Latini, Roberto ; Carbonieri, Emanuele ; Moretti, Luciano ; Rossi, Maria Grazia ; Ciricugno, Santo ; Milani, Valentina ; Marchioli, Roberto ; Struck, Joachim ; Bergmann, Andreas ; Maggioni, Aldo P. ; Tognoni, Gianni ; Tavazzi, Luigi. / The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure : Data from the GISSI-heart failure (GISSI-HF) trial. In: European Journal of Heart Failure. 2010 ; Vol. 12, No. 4. pp. 338-347.
@article{c309ef1889ce4935b967cafba3fc4b28,
title = "The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: Data from the GISSI-heart failure (GISSI-HF) trial",
abstract = "Aims Though various neurohormonal systems are concurrently activated during heart failure (HF), their biological effectors are not always easy to measure due to their short life in vivo, instability in biological samples, or very low concentrations. We measured the plasma concentrations of four stable precursor fragments of neurohormonal systems in patients with chronic HF and evaluated their relationship with outcome.Methods and resultsThis study was performed in 1237 patients with chronic and stable HF enrolled in the GISSI-heart failure trial (GISSI-HF). The following four precursor fragments, mid-regional pro-atrial natriuretic peptide (MR-proANP), mid-regional pro-adrenomedullin (MR-proADM), C-terminal pro-endothelin-1 (CT-proET-1) and C-terminal pro-vasopressin (CT-proAVP or copeptin), were measured at randomization and after 3 months. Baseline concentrations were independent predictors of clinical outcome (median follow-up 3.9 years). The addition of MR-proANP improved net reclassification for mortality when added to multivariable models based on clinical risk factors alone [net reclassification improvement (NRI) = 0.12, P = 0.0007] or together with NT-proBNP (NRI = 0.06, P = 0.01). Changes in MR-proANP concentrations were related to mortality [HR (95 CI) 1.38 (0.99-1.93), P = 0.0614 and 1.58 (1.13-2.21), P = 0.0078 in the middle and highest vs. lowest tertiles], while changes in the other markers were not.ConclusionIn patients with chronic and stable HF enrolled in a multicentre, randomized, clinical trial, measurement of stable precursor fragments of vasoactive peptides provided prognostic information independent of natriuretic peptides which are currently the best biomarkers for risk stratification.",
keywords = "Adrenomedullin, Endothelin, Heart failure, Natriuretic peptides, Prognosis, Vasopressin",
author = "Serge Masson and Roberto Latini and Emanuele Carbonieri and Luciano Moretti and Rossi, {Maria Grazia} and Santo Ciricugno and Valentina Milani and Roberto Marchioli and Joachim Struck and Andreas Bergmann and Maggioni, {Aldo P.} and Gianni Tognoni and Luigi Tavazzi",
year = "2010",
month = "4",
doi = "10.1093/eurjhf/hfp206",
language = "English",
volume = "12",
pages = "338--347",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "John Wiley & Sons, Ltd",
number = "4",

}

TY - JOUR

T1 - The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure

T2 - Data from the GISSI-heart failure (GISSI-HF) trial

AU - Masson, Serge

AU - Latini, Roberto

AU - Carbonieri, Emanuele

AU - Moretti, Luciano

AU - Rossi, Maria Grazia

AU - Ciricugno, Santo

AU - Milani, Valentina

AU - Marchioli, Roberto

AU - Struck, Joachim

AU - Bergmann, Andreas

AU - Maggioni, Aldo P.

AU - Tognoni, Gianni

AU - Tavazzi, Luigi

PY - 2010/4

Y1 - 2010/4

N2 - Aims Though various neurohormonal systems are concurrently activated during heart failure (HF), their biological effectors are not always easy to measure due to their short life in vivo, instability in biological samples, or very low concentrations. We measured the plasma concentrations of four stable precursor fragments of neurohormonal systems in patients with chronic HF and evaluated their relationship with outcome.Methods and resultsThis study was performed in 1237 patients with chronic and stable HF enrolled in the GISSI-heart failure trial (GISSI-HF). The following four precursor fragments, mid-regional pro-atrial natriuretic peptide (MR-proANP), mid-regional pro-adrenomedullin (MR-proADM), C-terminal pro-endothelin-1 (CT-proET-1) and C-terminal pro-vasopressin (CT-proAVP or copeptin), were measured at randomization and after 3 months. Baseline concentrations were independent predictors of clinical outcome (median follow-up 3.9 years). The addition of MR-proANP improved net reclassification for mortality when added to multivariable models based on clinical risk factors alone [net reclassification improvement (NRI) = 0.12, P = 0.0007] or together with NT-proBNP (NRI = 0.06, P = 0.01). Changes in MR-proANP concentrations were related to mortality [HR (95 CI) 1.38 (0.99-1.93), P = 0.0614 and 1.58 (1.13-2.21), P = 0.0078 in the middle and highest vs. lowest tertiles], while changes in the other markers were not.ConclusionIn patients with chronic and stable HF enrolled in a multicentre, randomized, clinical trial, measurement of stable precursor fragments of vasoactive peptides provided prognostic information independent of natriuretic peptides which are currently the best biomarkers for risk stratification.

AB - Aims Though various neurohormonal systems are concurrently activated during heart failure (HF), their biological effectors are not always easy to measure due to their short life in vivo, instability in biological samples, or very low concentrations. We measured the plasma concentrations of four stable precursor fragments of neurohormonal systems in patients with chronic HF and evaluated their relationship with outcome.Methods and resultsThis study was performed in 1237 patients with chronic and stable HF enrolled in the GISSI-heart failure trial (GISSI-HF). The following four precursor fragments, mid-regional pro-atrial natriuretic peptide (MR-proANP), mid-regional pro-adrenomedullin (MR-proADM), C-terminal pro-endothelin-1 (CT-proET-1) and C-terminal pro-vasopressin (CT-proAVP or copeptin), were measured at randomization and after 3 months. Baseline concentrations were independent predictors of clinical outcome (median follow-up 3.9 years). The addition of MR-proANP improved net reclassification for mortality when added to multivariable models based on clinical risk factors alone [net reclassification improvement (NRI) = 0.12, P = 0.0007] or together with NT-proBNP (NRI = 0.06, P = 0.01). Changes in MR-proANP concentrations were related to mortality [HR (95 CI) 1.38 (0.99-1.93), P = 0.0614 and 1.58 (1.13-2.21), P = 0.0078 in the middle and highest vs. lowest tertiles], while changes in the other markers were not.ConclusionIn patients with chronic and stable HF enrolled in a multicentre, randomized, clinical trial, measurement of stable precursor fragments of vasoactive peptides provided prognostic information independent of natriuretic peptides which are currently the best biomarkers for risk stratification.

KW - Adrenomedullin

KW - Endothelin

KW - Heart failure

KW - Natriuretic peptides

KW - Prognosis

KW - Vasopressin

UR - http://www.scopus.com/inward/record.url?scp=77950230145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950230145&partnerID=8YFLogxK

U2 - 10.1093/eurjhf/hfp206

DO - 10.1093/eurjhf/hfp206

M3 - Article

C2 - 20097683

AN - SCOPUS:77950230145

VL - 12

SP - 338

EP - 347

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 4

ER -